Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China.
Department of Electrophysiology, the First Affiliated Hospital of USTC, Division of life sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China.
Drug Des Devel Ther. 2024 Jun 21;18:2475-2484. doi: 10.2147/DDDT.S459618. eCollection 2024.
Ciprofol is a recently developed short-acting gamma-aminobutyric acid receptor agonist with a higher potency than that of propofol. As a new sedative drug, there are few clinical studies on ciprofol. We sought to examine the safety and efficacy of ciprofol use for general anesthesia in neurosurgical individuals undergoing neurosurgical surgery with intraoperative neurophysiological monitoring (IONM).
This single-center, non-inferiority, single-blind, randomized controlled trial was conducted from September 13, 2022 to September 22, 2023. 120 patients undergoing elective microvascular decompression surgery (MVD) with IONM were randomly assigned to receive either ciprofol or propofol. The primary outcome of this study was the amplitude of intraoperative compound muscle action potential decline, and the secondary outcome included the indexes related to neurophysiological monitoring and anesthesia outcomes.
The mean values of the primary outcome in the ciprofol group and the propofol group were 64.7±44.1 and 53.4±35.4, respectively. Furthermore, the 95% confidence interval of the difference was -25.78 to 3.12, with the upper limit of the difference being lower than the non-inferiority boundary of 6.6. Ciprofol could achieve non-inferior effectiveness in comparison with propofol in IONM of MVD. The result during anesthesia induction showed that the magnitude of the blood pressure drop and the incidence of injection pain in the ciprofol group were significantly lower than those in the propofol group (P<0.05). The sedative drug and norepinephrine consumption in the ciprofol group was significantly lower than that in the propofol group (P<0.05).
Ciprofol is not inferior to propofol in the effectiveness and safety of IONM and the surgical outcome. Concurrently, ciprofol is more conducive to reducing injection pain and improving hemodynamic stability, which may be more suitable for IONM-related surgery, and has a broad application prospect.
西普罗夫是一种新型的、作用时间较短的γ-氨基丁酸受体激动剂,其效力强于丙泊酚。作为一种新型镇静药物,目前关于西普罗夫的临床研究较少。本研究旨在探讨西普罗夫在接受术中神经生理监测(IONM)的神经外科手术患者全身麻醉中的安全性和有效性。
这是一项单中心、非劣效性、单盲、随机对照试验,于 2022 年 9 月 13 日至 2023 年 9 月 22 日进行。120 例行 IONM 的择期微血管减压术(MVD)患者被随机分为西普罗夫组或丙泊酚组。本研究的主要结局是术中复合肌肉动作电位下降幅度,次要结局包括与神经生理监测和麻醉结果相关的指标。
西普罗夫组和丙泊酚组的主要结局平均值分别为 64.7±44.1 和 53.4±35.4。此外,差值的 95%置信区间为-25.78 至 3.12,差值的上限低于 6.6 的非劣效性边界。西普罗夫在 MVD 的 IONM 中可达到与丙泊酚相当的有效性。麻醉诱导时,西普罗夫组的血压下降幅度和注射痛发生率明显低于丙泊酚组(P<0.05)。西普罗夫组镇静药物和去甲肾上腺素的消耗量明显低于丙泊酚组(P<0.05)。
西普罗夫在 IONM 效果和安全性以及手术结果方面不劣于丙泊酚。同时,西普罗夫更有利于减轻注射痛和改善血流动力学稳定性,可能更适合与 IONM 相关的手术,具有广阔的应用前景。